Concepedia

Kunal Kumar

KK

25

Publications

1.2K

Citations

20

H-Index

2010

Active since

Affiliations

Icahn School of Medicine at Mount Sinai(Current)

Discovery Institute

Stony Brook University

Colorado State University

AstraZeneca (United Kingdom)

Kunal Kumar is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

2010–2024

25

Publications

25

Novel Trisubstituted Benzimidazoles, Targeting <i>Mtb</i> FtsZ, as a New Class of Antitubercular Agents

Kunal Kumar, Divya Awasthi, Seung-Yub Lee et al. · Journal of Medicinal Chemistry · 2010 · 170 citations · Full text

, , +17

GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration

Courtney Ackeifi, Peng Wang, Esra Karaköse et al. · Science Translational Medicine · 2020 · 116 citations · Full text

, , +22

Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation

Kunal Kumar, Peng Wang, Roberto Sánchez et al. · Journal of Medicinal Chemistry · 2018 · 76 citations · Full text

SAR Studies on Trisubstituted Benzimidazoles as Inhibitors of <i>Mtb</i> FtsZ for the Development of Novel Antitubercular Agents

Divya Awasthi, Kunal Kumar, Susan E. Knudson et al. · Journal of Medicinal Chemistry · 2013 · 75 citations · Full text

, , +21

Thiazolopyridine Ureas as Novel Antitubercular Agents Acting through Inhibition of DNA Gyrase B

Manoj Kale, Anandkumar Raichurkar, Shahul Hameed P et al. · Journal of Medicinal Chemistry · 2013 · 66 citations · Full text

, , +21

Rows per page

1–5 of 25